ALMATICA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALMATICA, and when can generic versions of ALMATICA drugs launch?
ALMATICA has nine approved drugs.
There are three US patents protecting ALMATICA drugs.
There are fifty-three patent family members on ALMATICA drugs in thirty-one countries and eighteen supplementary protection certificates in nine countries.
Summary for ALMATICA
| International Patents: | 53 |
| US Patents: | 3 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 9 |
Drugs and US Patents for ALMATICA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almatica | VENLAFAXINE BESYLATE | venlafaxine besylate | TABLET, EXTENDED RELEASE;ORAL | 215429-001 | Jun 29, 2022 | RX | Yes | Yes | 7,776,358 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-002 | Aug 27, 2021 | RX | Yes | No | 8,999,393 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Almatica | SERTRALINE HYDROCHLORIDE | sertraline hydrochloride | CAPSULE;ORAL | 215133-001 | Oct 4, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-002 | Jan 28, 2011 | AB2 | RX | Yes | No | 7,438,927 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-004 | Feb 16, 2022 | RX | Yes | No | 8,999,393 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-003 | Apr 18, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALMATICA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-001 | Sep 20, 1990 | 4,472,380 | ⤷ Try a Trial |
| Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-001 | Jan 28, 2011 | 6,723,340 | ⤷ Try a Trial |
| Almatica | VENLAFAXINE BESYLATE | venlafaxine besylate | TABLET, EXTENDED RELEASE;ORAL | 215429-001 | Jun 29, 2022 | 6,717,015 | ⤷ Try a Trial |
| Almatica | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-002 | Jul 20, 1989 | 4,374,829*PED | ⤷ Try a Trial |
| Almatica | GRALISE | gabapentin | TABLET;ORAL | 022544-002 | Jan 28, 2011 | 8,333,992 | ⤷ Try a Trial |
| Almatica | MACROBID | nitrofurantoin; nitrofurantoin, macrocrystalline | CAPSULE;ORAL | 020064-001 | Dec 24, 1991 | 4,772,473 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALMATICA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 300 mg and 600 mg | ➤ Subscribe | 2011-10-31 |
Premature patent expirations for ALMATICA
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| ⤷ Try a Trial | ⤷ Try a Trial |
International Patents for ALMATICA Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 094391 | ⤷ Try a Trial |
| Mexico | PA04003946 | ⤷ Try a Trial |
| Croatia | P20210236 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 03035040 | ⤷ Try a Trial |
| Mexico | 2007001187 | ⤷ Try a Trial |
| Poland | 2943185 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALMATICA Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2236132 | 300714 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718 |
| 0502314 | C300095 | Netherlands | ⤷ Try a Trial | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
| 0480717 | 98C0025 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
| 0347066 | C300155 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ESCITALOPRAM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER ESCITALOPRAMOXALAAT; REGISTRATION NO/DATE: RVG 30490 - RVG 30497 20040427 |
| 0502314 | SPC/GB02/037 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| 0347066 | SPC/GB02/049 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ESCITALOPRAM OXALATE; REGISTERED: SE 17084/85/86/87 20011207; UK PL 13761/0008 20020610; UK PC 13761/0009 20020610; UK PL 13761/0010 20020610; UK PL 13761/0011 20020610; UK PL 13761/0012 20020610; UK PL 13761/0013 20020610; UK PL 13761/00014 20020610; UK PL 13761/0015 20020610 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
